新型冠状病毒2型蛋白酶抑制剂的快速耐药性分析
Rapid resistance profiling of SARS-CoV-2 protease inhibitors.
作者信息
Moghadasi Seyed Arad, Biswas Rayhan G, Harki Daniel A, Harris Reuben S
机构信息
University of Minnesota, Minneapolis, Minnesota, USA, 55455.
Howard Hughes Medical Institute, University of Texas Health San Antonio, San Antonio, Texas, USA, 78229.
出版信息
bioRxiv. 2023 Feb 27:2023.02.25.530000. doi: 10.1101/2023.02.25.530000.
Resistance to nirmatrelvir (Paxlovid) has been shown by multiple groups and may already exist in clinical SARS-CoV-2 isolates. Here a panel of SARS-CoV-2 main protease (M) variants and a robust cell-based assay are used to compare the resistance profiles of nirmatrelvir, ensitrelvir, and FB2001. The results reveal distinct resistance mechanisms ("fingerprints") and indicate that these next-generation drugs have the potential to be effective against nirmatrelvir-resistant variants and .
多个研究团队已证实新冠病毒对奈玛特韦（Paxlovid）存在耐药性，且临床分离的新冠病毒毒株中可能已存在耐药情况。在此，我们使用一组新冠病毒主要蛋白酶（M）变体和一种强大的基于细胞的检测方法，来比较奈玛特韦、恩赛特韦和FB2001的耐药谱。结果揭示了不同的耐药机制（“指纹”），并表明这些新一代药物有可能有效对抗耐奈玛特韦的变体。
Zotero 插件